{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:08:07Z","timestamp":1791331687532,"version":"4.3.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:00:00Z","timestamp":1606608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Hellenic Society for Chemotherapy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Infections caused by KPC-producing Klebsiella pneumoniae (Kp) are associated with high mortality. Therefore, new treatment options are urgently required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the outcomes and predictors of mortality in patients with KPC- or OXA-48-Kp infections treated with ceftazidime\/avibactam with an emphasis on KPC-Kp bloodstream infections (BSIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre prospective observational study was conducted between January 2018 and March 2019. Patients with KPC- or OXA-48-Kp infections treated with ceftazidime\/avibactam were included in the analysis. The subgroup of patients with KPC-Kp BSIs treated with ceftazidime\/avibactam was matched by propensity score with a cohort of patients whose KPC-Kp BSIs had been treated with agents other than ceftazidime\/avibactam with in vitro activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and forty-seven patients were identified; 140 were infected with KPC producers and 7 with OXA-48 producers. For targeted therapy, 68 (46.3%) patients received monotherapy with ceftazidime\/avibactam and 79 (53.7%) patients received ceftazidime\/avibactam in combination with at least another active agent. The 14 and 28\u2009day mortality rates were 9% and 20%, respectively. The 28\u2009day mortality among the 71 patients with KPC-Kp BSIs treated with ceftazidime\/avibactam was significantly lower than that observed in the 71 matched patients, whose KPC-Kp BSIs had been treated with agents other than ceftazidime\/avibactam (18.3% versus 40.8%; P\u2009=\u20090.005). In the Cox proportional hazards model, ultimately fatal disease, rapidly fatal disease and Charlson comorbidity index \u22652 were independent predictors of death, whereas treatment with ceftazidime\/avibactam-containing regimens was the only independent predictor of survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ceftazidime\/avibactam appears to be an effective treatment against serious infections caused by KPC-Kp.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaa503","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T15:12:42Z","timestamp":1605280362000},"page":"775-783","source":"Crossref","is-referenced-by-count":102,"title":["Ceftazidime\/avibactam in the era of carbapenemase-producing\n                    <i>Klebsiella pneumoniae<\/i>\n                    : experience from a national registry study"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-0239","authenticated-orcid":false,"given":"I","family":"Karaiskos","sequence":"first","affiliation":[{"name":"Hygeia General Hospital, 1st Department of Internal Medicine - Infectious Diseases, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G L","family":"Daikos","sequence":"additional","affiliation":[{"name":"Laiko General Hospital, 1st Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gkoufa","sequence":"additional","affiliation":[{"name":"Laiko General Hospital, 1st Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Adamis","sequence":"additional","affiliation":[{"name":"Peripheral General Hospital Athens Giorgos Gennimatas, 1st Department of Internal Medicine and Infectious Diseases Unit, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Stefos","sequence":"additional","affiliation":[{"name":"University of Thessaly, Larissa, Department of Medicine and Research Laboratory of Internal Medicine, Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Symbardi","sequence":"additional","affiliation":[{"name":"Thriaseio Geniko Nosokomeio Elefsinas, 1st Department of Internal Medicine, Magoula of Elefsina, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Chrysos","sequence":"additional","affiliation":[{"name":"Peripheral General Hospital of Peiraias Tzaneio, 2nd Department of Internal Medicine and Infectious Diseases Unit, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Filiou","sequence":"additional","affiliation":[{"name":"Sotiria General Hospital of Chest Diseases of Athens, Intensive Care Unit, 1st Department of Respiratory Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Basoulis","sequence":"additional","affiliation":[{"name":"Laiko General Hospital, 1st Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Mouloudi","sequence":"additional","affiliation":[{"name":"Ippokrateio General Hospital of Thessaloniki, Intensive Care Unit, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Galani","sequence":"additional","affiliation":[{"name":"Hygeia General Hospital, 1st Department of Internal Medicine - Infectious Diseases, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Akinosoglou","sequence":"additional","affiliation":[{"name":"University of Patras, Department of Medicine, Medical School, Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Arvaniti","sequence":"additional","affiliation":[{"name":"Geniko Nosokomeio Thessalonikis Papageorgiou, Intensive Care Unit and Antimicrobial Stewardship Unit, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Masgala","sequence":"additional","affiliation":[{"name":"Konstantopouleio General Hospital Neas Ionias Patesion, 1st Department of Internal Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Petraki","sequence":"additional","affiliation":[{"name":"Mediterraneo Hospital, Intensive Care Unit, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Papadimitriou","sequence":"additional","affiliation":[{"name":"General Hospital of Lamia, Department of Internal Medicine, Lamia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-9848","authenticated-orcid":false,"given":"I","family":"Galani","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens Faculty of Medicine, Infectious Diseases Laboratory, 4th Department of Internal Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Poulakou","sequence":"additional","affiliation":[{"name":"Sotiria General Hospital of Chest Diseases of Athens, 3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Routsi","sequence":"additional","affiliation":[{"name":"Evaggelismos Hospital, Intensive Care Unit, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Giamarellou","sequence":"additional","affiliation":[{"name":"Hygeia General Hospital, 1st Department of Internal Medicine - Infectious Diseases, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Hellenic Ceftazidime\/Avibactam Registry Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Papoutsaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Papadogeorgaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Tsapas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Astriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Romanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Makronassios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Giona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Pontikis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Gatselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Michailidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Gogos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,29]]},"reference":[{"key":"2021021208575571400_dkaa503-B1","year":"2011"},{"key":"2021021208575571400_dkaa503-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2021021208575571400_dkaa503-B3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/joim.12342","article-title":"Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control","volume":"277","author":"T\u00e4ngd\u00e9n","year":"2015","journal-title":"J Intern Med"},{"key":"2021021208575571400_dkaa503-B4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/1469-0691.12697","article-title":"Treating infections caused by carbapenemase-producing Enterobacteriaceae","volume":"20","author":"Tzouvelekis","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2021021208575571400_dkaa503-B5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2021021208575571400_dkaa503-B6","doi-asserted-by":"crossref","first-page":"pii=30062","DOI":"10.2807\/1560-7917.ES.2015.20.45.30062","article-title":"Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015","volume":"20","author":"Albiger","year":"2015","journal-title":"Euro Surveill"},{"key":"2021021208575571400_dkaa503-B7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpubh.2019.00151","article-title":"The \u201cold\u201d and the \u201cnew\u201d antibiotics for MDR Gram-negative pathogens: for whom, when, and how","volume":"7","author":"Karaiskos","year":"2019","journal-title":"Front Public Health"},{"key":"2021021208575571400_dkaa503-B8","doi-asserted-by":"crossref","first-page":"pii=1700775","DOI":"10.2807\/1560-7917.ES.2018.23.30.1700775","article-title":"Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016","volume":"23","author":"Galani","year":"2018","journal-title":"Euro Surveill"},{"key":"2021021208575571400_dkaa503-B9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/17425255.2019.1563071","article-title":"Novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens","volume":"15","author":"Karaiskos","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2021021208575571400_dkaa503-B10","year":"2016"},{"key":"2021021208575571400_dkaa503-B11","year":"2018"},{"key":"2021021208575571400_dkaa503-B12","year":"2020"},{"key":"2021021208575571400_dkaa503-B13","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575571400_dkaa503-B14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021021208575571400_dkaa503-B15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by KPC-producing Klebsiella pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021021208575571400_dkaa503-B16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"2021021208575571400_dkaa503-B17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"2021021208575571400_dkaa503-B18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2021021208575571400_dkaa503-B19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archinte.1962.03620240038007","article-title":"Gram-negative bacteremia. II. Clinical, laboratory and therapeutic observations","volume":"110","author":"McCabe","year":"1962","journal-title":"Arch Intern Med"},{"key":"2021021208575571400_dkaa503-B20","year":"2012"},{"key":"2021021208575571400_dkaa503-B21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.cmi.2018.09.014","article-title":"Combining VITEK\u00ae 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility","volume":"25","author":"Lellouche","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2021021208575571400_dkaa503-B22"},{"key":"2021021208575571400_dkaa503-B23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"2021021208575571400_dkaa503-B24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2021021208575571400_dkaa503-B25","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575571400_dkaa503-B26","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021021208575571400_dkaa503-B27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021021208575571400_dkaa503-B28","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/14787210.2017.1410434","article-title":"Combination therapy for extensively-drug resistant Gram-negative bacteria","volume":"15","author":"Karaiskos","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2021021208575571400_dkaa503-B29","doi-asserted-by":"crossref","first-page":"e01964-16","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575571400_dkaa503-B30","doi-asserted-by":"crossref","first-page":"e02320-19","DOI":"10.1128\/AAC.02320-19","article-title":"Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients","volume":"64","author":"Tsolaki","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575571400_dkaa503-B31","doi-asserted-by":"crossref","first-page":"ofz522","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-world experience with ceftazidime-avibactam for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021021208575571400_dkaa503-B32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","article-title":"Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae","volume":"24","author":"Falcone","year":"2020","journal-title":"Crit Care"},{"key":"2021021208575571400_dkaa503-B33","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021021208575571400_dkaa503-B34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis","volume":"54","author":"Onorato","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2021021208575571400_dkaa503-B35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/antibiotics9070388","article-title":"Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis","volume":"9","author":"Fiore","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2021021208575571400_dkaa503-B36","doi-asserted-by":"crossref","first-page":"e02497-17","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575571400_dkaa503-B37","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021021208575571400_dkaa503-B38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021021208575571400_dkaa503-B39","doi-asserted-by":"crossref","first-page":"e00592","DOI":"10.1128\/AAC.00592-18","article-title":"In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575571400_dkaa503-B40","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021021208575571400_dkaa503-B41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","article-title":"Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam","volume":"53","author":"De la Calle","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2021021208575571400_dkaa503-B42","doi-asserted-by":"crossref","first-page":"e00079-17","DOI":"10.1128\/AAC.00079-17","article-title":"In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575571400_dkaa503-B43","doi-asserted-by":"crossref","first-page":"763.e5\u20138","DOI":"10.1016\/j.cmi.2019.03.011","article-title":"Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam","volume":"25","author":"Galani","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2021021208575571400_dkaa503-B44","doi-asserted-by":"crossref","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575571400_dkaa503-B45","doi-asserted-by":"crossref","first-page":"516.e1","DOI":"10.1016\/j.cmi.2019.11.011","article-title":"Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime\/avibactam: epidemiology and genomic characterization","volume":"26","author":"Gaibani","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2021021208575571400_dkaa503-B46","doi-asserted-by":"crossref","first-page":"pii=2000028","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000028","article-title":"Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019","volume":"25","author":"Galani","year":"2020","journal-title":"Euro Surveill"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/775\/36241166\/dkaa503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/775\/36241166\/dkaa503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T19:19:01Z","timestamp":1613157541000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/3\/775\/6010522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,29]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,29]]},"published-print":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa503","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,11,29]]}}}